Publications

AKB-9778 Publications and Presentations

COVID-19 Program

August 2020

---

A Novel Approach to Glaucoma  Treatment Targeting Tie2 in the  Conventional  Outflow Pathway

Presented at: Glaucoma 360 New Horizons in Pharmaceuticals, (2020)

---

Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression

Published in Ophthalmology (2016)

---

Presented at the Glaucoma 360 meeting in San Francisco CA 07 Feb 2020

Published in Current Diabetes Report (2016)

---

Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema

Published in Pharmaceuticals (2020)

---

Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling

Published in Acta Neuropathologica (2016)

---

Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2

Published in Ophthalmology (2015)

---

Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin

Published in The Journal of Experimental Medicine (2015)

---

Targeting VE-PTP activates Tie2 and stabilizes the ocular vasculature

Published in The Journal of Clinical Investigation (2014)

---

Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression

Published in The Journal of the National Cancer Institute (2013)

---

Inhibiting the Inhibitor: Targeting Vascular Endothelial Protein Tyrosine Phosphatase to Promote Tumor Vascular Maturation 

Published in The Journal of the National Cancer Institute (2013)

---

ARP-1536 Publications

Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin

Published in The Journal of Experimental Medicine (2015)

---

Targeting VE-PTP activates Tie2 and stabilizes the ocular vasculature

Published in The Journal of Clinical Investigation (2014)

---

AKB-4924 Publications

Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation

Published in Mucosal Immunology (2017)

---

Inhibition of HIF Prolyl Hydroxylases Mitigate Gut Graft-Versus-Host Disease

Presented at American Society of Hematology Annual Meeting (2016)

---

Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis.

Published in Inflammatory Bowel Disease (2015)

---

Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.

Published in Mucosal Immunology (2014)

---

Transmigrating Neutrophils Shape the Mucosal Microenvironment through Localized Oxygen Depletion to Influence Resolution of Inflammation

Published in Immunity (2014)

---

A New Pharmacological Agent (AKB-4924) Stabilizes Hypoxia Inducible Factor (HIF) and Increases Skin Innate Defenses Against Bacterial Infection

Published in Journal of Molecular Medicine (2012)

---